Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2021 Earnings Conference Call March 31, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations Darrin Uecker - President & Chief Executive Officer Ed Ebbers - Executive Vice President, General Manager of Dermatology Sandy Gardiner - Executive Vice President & Chief Financial Officer Conference Call Participants Chris Cooley - Stephens Anthony Vendetti - Maxim Group Operator Good afternoon and welcome to the Pulse Biosciences' Fourth Quarter and Full ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________ Form 10-K ____________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 _____________________________________ ...

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q3 2021 Earnings Conference Call November 15, 2021 4:30 PM ET Company Participants Philip Taylor - Investor Relations Darrin Uecker - President & Chief Executive Officer Ed Ebbers - Executive Vice President, General Manager of Dermatology Sandy Gardiner - Executive Vice President & Chief Financial Officer Conference Call Participants RK - H.C. Wainwright Chris Cooley - Stephens Anthony Vendetti - Maxim Group Operator Greetings and welcome to Pulse Biosciences' Third Qua ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ Form 10-Q ___________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34899 ___________________________________ Pulse Bio ...

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q2 2021 Earnings Conference Call August 9, 2021 4:30 PM ET Company Participants Philip Taylor - Investor Relations Darrin Uecker - President & Chief Executive Officer, Ed Ebbers - Executive Vice President, General Manager of Dermatology Sandy Gardiner - Executive Vice President & Chief Financial Officer Conference Call Participants Chris Cooley - Stephens Anthony Vendetti - Maxim Group Sean Lee - H.C. Wainwright Operator Greetings and welcome to Pulse Biosciences' Seco ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ Form 10-Q ___________________________________ (Mark One) Or x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 Delaware 46-5696597 (State or other jurisdiction of incorporation or organization) ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 3957 Point Eden Way Hayward, CA 945 ...

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q1 2021 Results Earnings Conference Call May 10, 2021 4:30 PM ET Company Participants Philip Taylor - Investor Relations, Vice President at Gilmartin Group LLC Darrin Uecker - President, Chief Executive Officer Sandra Gardiner - Executive Vice President, Chief Financial Officer Ed Ebbers - Executive Vice President, General Manager of Dermatology Conference Call Participants Anthony Vendetti - Maxim Group Sean Kang - H.C. Wainwright Operator Greeting and welcome to the P ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ Form 10-Q ___________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34899 ___________________________________ Pulse Bioscie ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________ Form 10-K ____________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 _____________________________________ ...

Pulse Biosciences (Nasdaq : PLSE) February 2021 Forward-looking statements This presentation by Pulse Biosciences, Inc., contain estimates and forward-looking statements as of February 3, 2021 including, among others, statements regarding Pulse Biosciences' future business plans, products, commercial applications, intellectual property strategy, clinical trials, regulatory processes and pathways, and markets for its technologies, as well as patient and physician behavior and preferences and other future eve ...